

CoNCERT Pharmaceuticals Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 05-Aug-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Product Portfolio Summary..... 8

Product Portfolio Drugs..... 12

[Return to Table of Contents](#)

CoNCERT Pharmaceuticals Inc

COMPANY OVERVIEW

Company Name	CoNCERT Pharmaceuticals Inc
Parent Company Name	CoNCERT Pharmaceuticals Inc
Website	http://www.concertpharma.com/
Country	US
Number of Drugs in Active Development	6
Number of Inactive Drugs	18
Number of Patents as Owner	156
Number of Patents as Third Party	1
Number of Deals	8
Key Indications	Neuropathic pain,Epilepsy,Renal disease,Inflammatory disease,Cancer,Pain,Diabetic nephropathy,Multiple myeloma,Brain injury,HIV infection,Hypertension,Psoriasis
Key Target-based Actions	NMDA receptor antagonist,GABA A receptor modulator,PDE inhibitor,GABA B receptor agonist,Calcium channel inhibitor T-type,HIV protease inhibitor,CFTR stimulator,EGFR family tyrosine kinase receptor inhibitor,HIV-1 protease inhibitor,Opioid receptor sigma agonist 1
Key Technologies	Small molecule therapeutic,Oral formulation,Drug combination,Antibiotic,Capsule formulation,Controlled release formulation,Formulation preservation,Crystalline form,Prodrug,Closed heterocyclic ring synthesis,Condensational synthesis,Labeling

COMPANY PROFILE

SUMMARY

CoNCERT Pharmaceuticals Inc is a Boston-based pharmaceutical company which uses chemical methodology, involving an innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, to create bioavailable drug candidates.

EARLY R&D

By May 2009, Concert Pharmaceuticals was investigating deuterium analogs of rimonabant and mosapride.

By January 2008, the company was researching an HER2/EGFR inhibitor, an antiviral, a cytokine inhibitor and a number of antibiotics, for deuteration. By June 2008, CoNCERT was also researching a protease inhibitor for the potential treatment of HIV, an antifibrotic agent, an NMDA antagonist/ sigma agonist for the potential treatment of neuropathic pain, an antibacterial for the potential treatment of MRSA, an antipsychotic for the potential treatment of schizophrenia, a PDE-5 inhibitor for the potential treatment pulmonary arterial hypertension and benign prostate hyperplasia, a calcium modulator for the potential treatment of hyperparathyroidism, an EGFR inhibitor for the potential treatment of tumors and a CCR5 antagonist for the potential treatment of HIV.

FINANCIAL

In February 2014, CoNCERT priced a planned IPO of its common stock at \$14 per share. Underwriters would be granted a 30-day option to purchase up to an additional 900,000 shares at the same price to cover over-allotments. The shares would trade on the NASDAQ Global Market under the ticker symbol 'CNCE'. At that time, the offering was expected to close on February 19, 2014. Later that month, the offering was closed; in March 2014, underwriters exercised their over-allotment option and purchased an additional 649,690 shares which increased a capital raise of approximately \$93 million; at that time, net proceeds of \$83.1 million was raised.

In April 2008, CoNCERT Pharmaceuticals raised \$37 million in a series C financing round. The company planned to use the funds to advance its deuterium chemistry platform and product pipeline.

In November 2006, CoNCERT raised \$48.5 million in series B financing.

[Return to Table of Contents](#)




In July 2006, CoNCERT raised \$10 million from a series A venture capital financing.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	2	5	7
Infectious disease	0	6	6
Cardiovascular disease	1	4	5
Inflammatory disease	1	3	4
Neoplasm	0	4	4
Psychiatric disorder	0	3	3
Musculoskeletal disease	1	2	3
Genitourinary disease	1	1	2
Gastrointestinal disease	1	1	2
Respiratory disease	1	1	2
Immune disorder	0	2	2
Injury	1	0	1
Hematological disease	0	1	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Phase 1 Clinical	2
Discovery	3
Discontinued	2
No Development Reported	16

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Screening/Evaluation	1	0	1	0	2
Drug - Development/Commercialization License	4	0	0	0	4
Drug - CRADA	1	0	0	0	1
Drug - Funding	1	0	0	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Genitourinary disease	0	3
Infectious disease	0	1
Cardiovascular disease	0	1
Psychiatric disorder	0	1

Trials by Phase

Phase	Ongoing	All
Phase 3	0	1
Phase 2	0	1
Phase 1	0	10

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

[Return to Table of Contents](#)



Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	61	0	61
Endocrine disease	44	0	44
Gastrointestinal disease	68	0	68
Genitourinary disease	65	0	65
Growth disorder	11	0	11
Hematological disease	34	0	34
Degeneration	14	0	14
Andrology	23	0	23
Immune disorder	57	0	57
Psychiatric disorder	33	0	33
Musculoskeletal disease	29	0	29
Neoplasm	53	0	53
Ocular disease	17	0	17
Genetic disorder	19	0	19
Metabolic disorder	40	0	40
Mouth disease	1	0	1
Neurological disease	79	0	79
Nutritional disorder	15	0	15
Respiratory disease	33	0	33
Infectious disease	40	0	40
Injury	6	0	6
Toxicity and intoxication	10	0	10
Inflammatory disease	47	0	47

[Return to Table of Contents](#)

Fatigue	3	0	3
Otorhinolaryngological disease	3	0	3
Gynecology and obstetrics	23	0	23
Dermatological disease	32	0	32
Ulcer	5	0	5

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

CTP-499

Drug Name	CTP-499
Key Synonyms	
Originator Company	CoNCERT Pharmaceuticals Inc
Active Companies	GlaxoSmithKline plc, CoNCERT Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Renal disease
Target-based Actions	PDE inhibitor
Other Actions	Anti-inflammatory, Fibrosuppressant, Antioxidant agent, Renal system agent
Technologies	Oral formulation, Controlled release formulation, Small molecule therapeutic
Last Change Date	09-Jul-2014

CTP-347

Drug Name	CTP-347
Key Synonyms	
Originator Company	CoNCERT Pharmaceuticals Inc
Active Companies	CoNCERT Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Hot flashes
Target-based Actions	
Other Actions	5-HT uptake inhibitor
Technologies	Oral formulation, Small molecule therapeutic
Last Change Date	09-Apr-2014

[Return to Table of Contents](#)

CTP-354

Drug Name	CTP-354
Key Synonyms	
Originator Company	CoNCERT Pharmaceuticals Inc
Active Companies	CoNCERT Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Muscle hypertonia, Neuropathic pain
Target-based Actions	GABA A receptor modulator
Other Actions	Analgesic, Anxiolytic
Technologies	Oral formulation, Small molecule therapeutic
Last Change Date	17-Jul-2014

C-10068

Drug Name	C-10068
Key Synonyms	
Originator Company	CoNCERT Pharmaceuticals Inc
Active Companies	Walter Reed Army Institute of Research, CoNCERT Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Brain injury, Neuropathic pain, Epilepsy
Target-based Actions	Opioid receptor sigma agonist 1
Other Actions	Analgesic, Antidepressant, Anticonvulsant agent, Neuroprotectant
Technologies	Oral formulation, Small molecule therapeutic
Last Change Date	15-May-2014

[Return to Table of Contents](#)

deuterated ivacaftor analogs (cystic fibrosis/COPD), Concert Pharmaceuticals

Drug Name	deuterated ivacaftor analogs (cystic fibrosis/COPD), Concert Pharmaceuticals
Key Synonyms	
Originator Company	CoNCERT Pharmaceuticals Inc
Active Companies	CoNCERT Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cystic fibrosis, Chronic obstructive pulmonary disease
Target-based Actions	CFTR stimulator
Other Actions	
Technologies	Oral formulation, Small molecule therapeutic
Last Change Date	15-May-2014

CTP-730

Drug Name	CTP-730
Key Synonyms	
Originator Company	CoNCERT Pharmaceuticals Inc
Active Companies	CoNCERT Pharmaceuticals Inc, Celgene Corp
Inactive Companies	
Highest Status	Discovery
Active Indications	Inflammatory disease
Target-based Actions	
Other Actions	Anticancer, Anti-inflammatory, Unspecified drug target
Technologies	Small molecule therapeutic
Last Change Date	15-May-2014

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)